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Abstract
Rationale: Currently, studies on adherence to inhaled medications
report average adherence over time. This measure does not account
for variations in the interval between doses, nor for errors in inhaler
use.
Objectives: To investigate whether adherence calculated as a
single area under the (concentration-time) curve (AUC) measure,
incorporating the interval between doses and inhaler technique, was
more reflective of patient outcomes than were current methods of
assessing adherence.
Methods:We attached a digital audio device (INhaler Compliance
Assessment) to a dry powder inhaler. This recorded when the inhaler
was used, and analysis of the audio data indicated if the inhaler had
been used correctly. These aspects of inhaler use were combined to
calculate adherence over time, as an AUC measure. Over a 3-month
period, a cohort of patients with asthma was studied. Adherence to a
twice-daily inhaler preventer therapy using this device and clinical
measures were assessed.
Measurements and Main Results: Recordings from 239
patients with severe asthma were analyzed. Average adherence that
was based on the dose counter was 84.4%, whereas the ratio of
expected to observed accumulatedAUC, actual adherence,was 61.8%
(P, 0.01). Of all the adherence measures, only adherence calculated
as AUC reflected changes in asthma quality of life, b-agonist reliever
use, and peak expiratory flow over the 3months (P, 0.05 compared
with other measures of adherence).
Conclusions: Adherence that incorporates the interval between
doses and inhaler technique, and calculated as AUC, is more
reflective of changes in quality of life and lung function than are the
currently used measures of adherence.
Clinical trial registered with www.clinicaltrials.gov (NCT 01529697).
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Electronic monitors are considered the gold
standard for objectively quantifying
adherence to inhaled therapy (1). Most
studies using electronic recording devices
have reported adherence as the mean
adherence, or the mean daily dose, over the
study period (2–4). However, this method
does not reflect variations in the way that
patients use their treatments. For example,
the mean adherence is the same whether
an individual took the medication
according to the prescribed schedule or
took all the doses in the first half of a dosing
period, leaving none in the second half.
Inhaler technique must be included in the
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assessment of adherence because an
individual may use his/her inhaler according
to the dosing schedule but with incorrect
technique, resulting in no medication being
delivered. In this case, the average use over
time is meaningless unless data on the
technique of use are also incorporated into
the calculation of adherence. Most electronic
recording devices do not assess whether the
inhaler was used correctly (5–12). Hence,
there is a need to develop a method to
quantify adherence that accounts for
variations in dosing schedules as well as
inhaler user technique.
We developed a device, INhaler
Compliance Assessment (INCA), which
makes a digital file each time the inhaler is
used (13). Analysis of this information
means that the time of use, the interval
between doses, and the proficiency of
the inhaler use can be assessed (13).
Technique errors identified by this
method include failing to prime the inhaler,
dispersing the medication by exhalation into
the inhaler after priming, and dose dumping
(14, 15). In addition, the acoustic features of
inhalation are highly reflective of objectively
measured peak inspiratory flow, meaning that
the device can estimate the peak inspiratory
flow at each inhalation (16), (17).
The aim of this study was to test the
hypothesis that by including the time of use,
the interval between doses, and the inhaler
technique, we could quantify adherence
as an area under the curve (AUC) and,
furthermore, determine whether adherence
calculated using AUC was more reflective of
patient outcomes than the current methods
of assessing adherence. Some of the results
of this study have been reported previously
in the form of an abstract (18).
Methods
Study Design
Patients for this study were prospectively
recruited from five specialty asthma clinics
in Ireland from January 2011 to December
2015. Participants included in this analysis
include all patients with asthma studied to
date, both those who participated in the pilot
preliminary study (n = 32) and those from
the single, blind, prospective, multicenter,
randomized controlled clinical trial
(n = 207) that followed. The full protocol of
the study has already been published (19).
All patients from both groups of the
randomized control trial were combined to
provide at least 6,000 audio files for analysis
(50% of prescribed inhalations over the
month for 200 patients).
On enrolment, the patients were shown
how to use the inhaler, and errors were
corrected using a 10-point checklist inhaler
proficiency score (20–22). Over the
following months (4, 8, and 12 wk), the
patients returned to the clinic, where
inhaler technique was checked and
improved if necessary, and adherence was
encouraged.
The primary end point of this study was
to describe inhaler adherence using a new
method of calculating adherence and its
relationship with clinical outcomes in
asthma, such as quality of life, disease
control, and lung physiology.
Participants
Inclusion criteria were patients who were
>18 years of age who had already been
prescribed therapy equivalent to step 3 or
higher in the Asthma Management
Guidelines (23, 24) and who, in addition,
had had at least one exacerbation treated
with systemic glucocorticoids in the
previous year. The dose of inhaled
corticosteroid and long-acting b-agonist
was not changed during the study.
Exclusion criteria included an
unwillingness to participate in a clinical
study or prior hypersensitivity to
salmeterol/fluticasone. Asthma diagnosis
was made using a clinician diagnosis
supported by one or more of the following:
obstructive spirometry with at least 12%
reversibility, a positive bronchial
provocation challenge, or variability in the
diurnal peak expiratory flow (PEF) of
.15%. All patients provided written
informed consent. The study was approved
by local hospitals’ ethics committees.
Electronic Adherence Monitor
We have reported previously the
development and validation of the INCA
audio recording device in 60 patients with a
total of 1,200 audio recordings (13). The
device contains a microphone, internal
clock, battery, and memory card with
plastic housing. It is attached to an inhaler
and records the audio associated with an
individual using his/her inhaler (Figure 1).
In previous studies, we have shown that
Figure 1. Photograph of the INhaler Compliance Assessment (INCA) device attached to a salmeterol/
fluticasone Diskus inhaler. The device contains a microphone, an internal clock, a memory card,
and some circuitry. Every time the inhaler device is opened, the INCA starts recording audio of the
patient using his/her inhaler with a date-time stamp.
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Figure 2. Calculation of adherence algorithm. Examples of patients prescribed a medication twice daily for 30 days are shown. Column A is an example of
a patient with perfect adherence over a 30-day period. Attempted adherence, fðATÞ, is perfect, 60 doses taken over 30 days. There were no missed doses
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inhaler errors such as low inspiratory
flow and exhalation into the inhaler are
identified easily. We have also shown that the
acoustic features of inhalation are directly
proportional to peak inspiratory flow (14, 16,
17). The device has a failure rate of ,2%;
it was developed at the Trinity Centre of
Bioengineering, Dublin, and is Conformite´
Europe´ene (CE) marked and manufactured
by Vitalograph Ltd., Ennis, Republic of
Ireland. The device is currently available for
use in research. Participants in this analysis
received an INCA-enabled salmeterol/
fluticasone Diskus inhaler each month.
Extraction of Features of Inhaler Use
and Calculating Adherence
Audio raters assessed each acoustic
recording for evidence of critical errors, as
described previously (13–15). Critical errors
in inhaler use, such as low inspiratory flow,
were classified as no dose, whereas
noncritical errors, such as vertical position
of the inhaler, were classified as a complete
dose.
The interval between doses was
calculated on the basis of drug half-life, and
the measurement of doses taken was related
to this drug interval (for this study, the
pharmacokinetic profile and drug half-life of
salmeterol were used). A dose taken within
one half-life of the drug, after the previous
dose, was counted as one dose. When the
interval between doses was greater than one
half-life and less than two half-lives, this was
considered 0.5 dose. In cases in which the
interval between doses was greater than four
half-lives, this was considered no dose.
Information collected on the time, the
interval between doses, and the technique of
inhaler use was combined to calculate an
AUC metric. Initially, the AUC is calculated
for the expected doses, denoted by f ðexÞ.
After this, the AUC is calculated for the
participant’s attempted dosing, denoted by
f ðatÞ. Attempted dosing refers to the
number of doses that patients attempt to
take (i.e., evidence of drug priming in the
acoustic analysis; these doses may be taken
correctly or incorrectly) and was used to
calculate the attempted adherence, f ðATÞ.
Attempted adherence f ðATÞ¼ f ðatÞ=f ðexÞ %
This value, relative to the expected doses,
f ðexÞ, gives information on overdosing,
denoted by f ðodÞ and missed doses,
denoted by f ðmdÞ. By removing doses
where a critical error has occurred, the
actual doses, denoted by f ðadÞ, may be
deduced. Subtracting this value from f ðATÞ
gives us the technique rate, denoted by
f ðteÞ.
Technique rate f ðteÞ ¼ f ðATÞ2 f ðadÞ ð%Þ
The interval adherence f ðiÞ is calculated as
the ratio of the attempted interval
adherence f ðiatÞ to the expected interval
adherence f ðiexÞ.
Interval adherence f ðiÞ ¼ f ðiatÞ
f ðiexÞ ð%Þ
Furthermore, by removing the technique
errors, we can calculate the actual adherence
f ðACÞ.
Actual  adherence  f ðACÞ ¼ f ðiÞ2 f ðteÞ ð%Þ
See Figure 2 for a graphical display of this
process and for a definition of terms.
Analysis of PEF
A similar method to that described above
was used to analyze PEF data. Expected PEF
was calculated on the basis of age, sex, and
height.
AMPEFAUC f ðAMÞ ¼ f ðRecorded AM PEFÞ
f ðExpected AM PEFÞ ð%Þ
PEF variability (25) was calculated as
the difference between A.M. and P.M.
PEF AUC.
AM  PM  variability  f ðAMPMÞ ¼ f ðAMÞ2 f ðPMÞð%Þ
Outcome Measures
At the end of each month, the INCA device
was collected from the participant. Audio
data were downloaded from each device to
provide information on inhaler use for the
previous month. Additional information
recorded at each visit included the findings
of the Asthma Quality of Life Questionnaire
(AQLQ) and the Asthma Control Test
(ACT), the patient’s self-reported reliever
medication use, PEF, and any recent
exacerbations. Change in AQLQ (26, 27)
was divided into those who did (improvers)
and did not (nonimprovers) have an
improvement of 0.5 points (the minimal
clinically important difference in AQLQ).
Change in PEF was also categorized into
improvers and nonimprovers on the basis
of a 10% cutoff (23, 24).
Statistical Analysis
Descriptive statistics were used to present
basic patient details for those included in
this analysis. Means and SDs are presented
for continuous variables, and frequencies
and percentages for categorical variables.
Figure 2. (Continued). and no technique errors, the interval between doses is within one half-life, and the actual adherence rate, fðACÞ, is 1.00 (100%).
Column B is an example in which the medication was taken only once daily for 30 days. The attempted adherence, fðATÞ, is half that of column
A and there were 30 missed doses over 30 days. In this example, there were no technique errors. Because of missing doses every day, the interval
between doses was also poor and fðACÞ is 0.50 (50%). Column C is an example of a patient who takes the medication (with no technique errors) every
day, twice a day, but with erratic timing. There was perfect attempted adherence, with no missed doses and no technique errors. Because of the
erratic time of use, for some doses that have an interval beyond the half-life of the drug, fðiÞ, the fðACÞ is reduced to 0.92 (92%). Finally, column D is an
example of a patient who takes the medication only once daily and makes a technique error for the first 15 days of the 30 days. Therefore, the fðATÞ is half
that expected (50%) because of the 30 missing doses. There were also 15 doses with technique errors, and because of missing doses, every day
the interval between doses was poor; therefore, the fðACÞ is 0.25 (25%).
Table 1. Baseline characteristics of the
study population
Baseline
Characteristic
Study
Population
No. patients 239
Age, yr 496 16.1
Male sex, No. (%) 91 (38)
FEV1, L/s 2.26 0.88
FEV1 % predicted 74.16 22.9
No. exacerbations in
the previous year
4.36 3.5
ACT V1 12.26 4.5
AQLQ V1 3.96 1.3
Patients’ reliever use,
No. (%)
Never 49 (21)
,1/wk 15 (6)
1/wk 8 (3)
2-5/wk 22 (9)
Every day 145 (61)
Definition of abbreviations: ACT = Asthma
Control Test (at visit 1); AQLQ = Asthma Quality
of Life Questionnaire (at visit 1).
Data are presented as mean6 SD unless
otherwise stated.
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For each patient and each month of data,
the following adherence measures were
calculated: dose counter (average
adherence), mean daily dose, f ðmdÞ, f ðodÞ,
f ðATÞ, f ðteÞ, and f ðACÞ. Baseline
adherence measures at Month 1 were
examined initially. We used t tests to
compare the means of these different
adherence rates. Proportions were
compared using a x2 analysis. Over the
3 months, differences in adherence
measures and associations with clinical
outcomes were examined using an
ordinary least-squares regression. Each
adherence measure regression coefficient
was compared with f ðACÞ for improvers
and nonimprovers separately. To compare
these coefficients, a test of linear
hypothesis after estimation was used, to
determine if the linear expressions were
equal.
Because there is no gold standard for
calculating adherence, a sensitivity
analysis was done by categorizing
adherence into good and poor on the
basis of an 80% cutoff for each adherence
measure. With this categorization, each
adherence measure’s sensitivity and
specificity at identifying improvers
and nonimprovers (AQLQ and PEF) and
controlled and uncontrolled (ACT) are
reported. All statistical analysis was
conducted using Stata Release 13
(StataCorp, College Station, TX).
Results
Participants
The clinical characteristics of the 239
participants included in this analysis can be
seen in Table 1. The patient cohort was
primarily female (62%) with a mean (SD)
age of 49 (16.1) years. A large proportion
of patients in this cohort had poorly
controlled asthma, with a mean AQLQ of
3.9 and ACT of 12.2, and 145 patients
(61%) used a short-acting b-agonist on
a daily basis.
Baseline Adherence to
Inhaled Therapy
In the first month, there were 11 device
failures (,6%), 5 devices (,3%) were lost,
and a further six patients (,3%) had
missing dose counter information. For the
first month, the total number of audio files
with evidence of drug priming was 7,973,
Table 2. Mean adherence for all patients
as calculated using different adherence
measures
Adherence
Measure
Mean6 SD
Actual adherence fðACÞ 61.86 28.5
Average adherence
from dose counter*
84.46 19.1
Mean daily dose 85.06 21.3
Attempted adherence* fðATÞ 79.46 20.7
Missed dose rate fðmdÞ 20.76 18.7
Overdose rate fðodÞ 6.66 9.2
Technique error rate fðteÞ 14.26 21.5
*The difference in the average adherence by
dose counter and attempted adherence is
caused by multiple blisters and some
unrecorded dose counters.
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Figure 3. Graphical representation of adherence calculated in a number of ways. The data used for this graph are the first month’s inhaler use by a cohort
of 217 (of 239) patients with asthma enrolled in a prospective adherence intervention clinical study who were asked to use a dry powder inhaler twice daily.
The actual adherence rate, fðACÞ, is significantly different from the adherence calculated using the current methods, that is, average adherence from
the dose counter and the mean daily dose, and the attempted rate, fðATÞ (the electronic time of use measure) (P, 0.001).
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compared with a total of 8,169 doses on the
dose counter (correlation coefficient =
0.981). The differences between the two
measures were caused by episodes of
multiple priming of the inhaler without
inhalation; this was recorded by the dose
counter as doses were taken. The mean
number of audio files per patient from the
60-dose Diskus inhaler was 486 10.8,
whereas the mean number of doses
recorded from the dose counter was
496 18.4.
Analysis of the time-stamped audio
data recorded to the INCA device showed
errors in inhaler handling, errors in
overdosing, and errors in missed doses. The
most common critical errors in inhaler use
included 308 events (3.1% of all attempted
doses) of low peak inspiratory flow (PIF)
and 283 events (2.8% of all attempted doses)
of exhalation into the device. Other errors
included multiple inhalations with no
breath hold and multiple priming of the
inhaler without inhalation. The mean
technique error rate, f ðteÞ; was 14.26
21.5%. The mean overdosing rate, f ðodÞ,
was 6.66 9.2%, and the mean missed doses
rate, f ðmdÞ, was 20.76 18.7%. Using the
AUC method described above and
accounting only for evidence of priming of
the inhaler, the mean attempted adherence,
f ðATÞ, was 79.46 20.7%. Combined with
the technique error rate, this meant that the
mean actual adherence, f ðACÞ, at 1 month
was 61.86 28.5%, significantly different
from f ðATÞ (P, 0.01) (Table 2 and
Figure 3).
INCA and dose counter data. Data for
both the dose counter and the INCA device
were available for 217 (91%) of the 239
patients. For these patients, the average dose
Table 3. Patients considered adherent using various measures of adherence, with
80% as a cutoff for good and poor adherence
Adherence
Measure
Good Adherence (>80%) Poor Adherence (<80%)
n Mean6 SD (%) n Mean6 SD (%)
Actual adherence fðACÞ 67 90.96 4.5 156 49.36 25.1
Average adherence from
dose counter
153 93.46 12.0 64 62.96 15.6
Mean daily dose 161 94.26 14.0 62 61.16 18.3
Attempted adherence fðATÞ 140 91.46 5.4 83 59.06 21.2
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Figure 4. Asthma quality of life (AQLQ) value was recorded on a monthly basis. The minimal clinically important improvement in AQLQ is a 0.5 increase.
Patients were divided into those who had a change in AQLQ >0.5 over 3 months (improvers) and those with a change ,0.5 over 3 months
(nonimprovers). (A) Relationship between the changes in AQLQ and the average adherence calculated from the Diskus dose counter is shown. Using this
method of calculation of adherence, paradoxically, nonimprovers had a higher level of adherence than did those who improved. (B) Relationship between
the changes in AQLQ and the mean daily dose is shown. Nonimprovers similarly showed no relationship between adherence and change in AQLQ.
(C ) Relationship between the changes in AQLQ and attempted adherence is shown. Nonimprovers had a higher adherence rate, for a bigger drop in
AQLQ, similar to mean daily dose; however, improvers had a better adherence rate as the improvement in AQLQ increased. (D) Relationship between the
changes in AQLQ and the actual adherence is shown. Nonimprovers had low adherence rates, which increased as the fall in AQLQ decreased, and
improvers had higher adherence rates, which improved as the change in AQLQ increased. There was a significant difference when comparing average
adherence (dose counter) with actual adherence and average adherence with attempted adherence (P, 0.01 and P, 0.03, respectively).
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counter adherence was 84.46 19.1% and
the mean daily dose was 85.06 21.3%.
Using an 80% cutoff to indicate good
adherence, 67 patients (30%) had good
f ðACÞ over the first month of inhaler use.
This was much lower than that calculated
using other adherence measures (Table 3).
As a result, the average adherence, using the
dose counter, had 37.1% sensitivity and
93.0% specificity, with a 90.2% positive and
a 46.2% negative predictive value to actual
adherence, f ðACÞ(Table 4).
Associations between Adherence
Measures and Clinical Outcomes
Quality of life. Patient-reported AQLQ
change from the start of the monitoring
period to the end of the study was analyzed.
The coefficient of the regression line for
the f ðACÞ was 1.1 for improvers and 2.2
for nonimprovers, both of which were
significantly different from f ðATÞ
(P< 0.01 and r2 = 0.2 for nonimprovers)
mean daily dose (P< 0.03 and r2 = 0.7 for
improvers, P, 0.02 and r2 = 0.2 for
nonimprovers), and average adherence
(P, 0.03 and r2 = 0.7 for improvers,
P< 0.02 and r2 = 0.2 for nonimprovers)
(Figure 4).
For the purpose of this analysis, an
AQLQ >5 was considered to be indicative
of a good quality-of-life score (26, 27). At
Month 3, both a good quality-of-life score
(AQLQ >5) and good adherence (>80%)
were seen in 17% of patients when
adherence was calculated by the f ðACÞ
method, compared with 36% when
adherence was calculated using the dose
counter (Table 5). In contrast, among
those with an AQLQ ,5, 35% had an
f ðACÞ ,80% and only 16% had an
average dose counter adherence ,80%
(P, 0.01, x2 test). The sensitivity and
specificity of the various measures of
adherence in identifying patients with an
improvement in AQLQ are shown in
Table 6.
Lung function. The mean (range)
variability between morning and evening
PEF (A.M. to P.M. variability) was 4.9%
(1–90) in Month 1, 5.6% (1–85) in Month
2, and 5.0% (1–80) in Month 3. Compared
with the other measures of adherence,
f ðACÞ demonstrated the greatest
correlation to A.M. P.M. PEF variability,
(P< 0.03 and r2 = 0.3) (Figure 5). The
sensitivity and specificity of the various
measures of adherence in identifying
patients with a >10% improvement in A.M.
PEF are shown in Table 6.
b-Agonist use. Patients who used their
short-acting b-agonist (SABA) every day had
a mean f ðACÞ of 59.06 30.2%, an average
adherence of 83.96 16.1%, a mean daily dose
of 84.76 19.4%, and a mean attempted
adherence of 79.76 19.5% [P, 0.01 when
all rates were compared with f ðACÞ].
Discussion
Both electronic recording devices and
manual dose counters are commonly used
to assess adherence in clinical trials.
Traditionally, adherence is judged to be
good when the average adherence is .80%
of expected use. However, there is no
scientific basis for assessing adherence as an
average value or that 80% adherence is
a valid way of demonstrating good
adherence. The purpose of this study was to
review some common methods of assessing
adherence and to compare these with a
proposed new method. The term adherence
refers to the way that a patient follows the
physician’s prescription, which is based on
the pharmacokinetic principles of the
medication. We reasoned that by using the
information recorded to the INCA device,
which records the time of use and the time
between doses, and adjusting for the
modifying effect on the dose administered
caused by incorrect user technique, we
could calculate adherence. To do this, we
calculated medication use as an AUC
metric, a measure commonly used to reflect
plasma drug concentration, and we tested
the relationship of this method of
calculating adherence to established
methods in a cohort of patients with
asthma (18, 19).
Despite inhaler training, adherence
education, and knowingly using an
electronic recording device, and despite
participating in a clinical trial focused on
promoting adherence, episodes of missed
doses, overuse, dose dumping, and critical
errors in inhaler use were all recorded. As a
result, adherence calculated in the proposed
manner was significantly lower than that
Table 4. Adherence measures compared with actual adherence
Adherence
Measure
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Average adherence
from dose counter
37.1 93.0 90.2 46.2
Mean daily dose 52.8 96.6 96.4 54.1
Attempted adherence 43.0 97.0 96.2 49.2
The table presents the sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) of the dose counter, the mean daily dose, and the attempted adherence in correctly
classifying good and poor adherence relative to the actual adherence (using the traditional 80% cutoff
for good adherence).
Table 5. Adherence rates at month 3 and their relationship with changes in
AQLQ and PEF
Adherence
Measure
PEF AQLQ
Improver*
(%)
Nonimprover
(%)
Improver†
(%)
Nonimprover
(%)
Actual adherence fðACÞ 68.56 28.4 65.76 27.6 66.46 28.4 64.46 27.3
Average adherence
from dose counter
87.26 13.0 89.46 14.5 87.26 13.8 88.66 15.3
Mean daily dose 84.46 13.7 84.06 16.3 83.36 15.2 83.66 16.5
Attempted adherence
fðATÞ
81.86 16.6 82.46 18.5 82.16 16.5 80.76 20.2
Definition of abbreviations: AQLQ = Asthma Quality of Life Questionnaire; PEF = peak expiratory flow.
*>10% improvement in A.M. PEF readings.
†>0.5 point improvement in AQLQ.
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quantified by other commonly used
methods, such as mean adherence (28–31)
or the mean daily dose (2, 32).
Over a 3-month period in which
adherence, AQLQ, ACT, PEF, and inhaled
b-agonist use were quantified, only actual
adherence [f ðACÞ] reflected the changes in
patient outcomes. In contrast, average
adherences calculated from the dose
counter, the mean daily dose, and the
attempted adherence [f ðATÞ] all failed to
distinguish between those who did and
did not have clinically meaningful
improvements in several related clinical
measures. For example, an inverse
relationship was found for nonimprovers,
between the currently used measures of
adherence and changes in AQLQ. In
addition, PEF correlated only with f ðACÞ,
with less morning-to-evening variability in
PEF associated with higher levels of f ðACÞ.
Likewise, significantly higher b-agonist
reliever use was associated with lower
f ðACÞ. These relationships were not seen
with other measures of adherence. These
results demonstrate the importance of
variation in the time of use and errors in
inhaler handling and emphasize the need to
incorporate this information into the
calculation of adherence.
Limitations
This study has several limitations. First, the
patients studied had already been prescribed
inhaled salmeterol/fluticasone for some
time. Hence, it is not too surprising that
there were relatively small changes in lung
function and quality of life. Furthermore,
the duration of follow-up was relatively
short and possibly not of sufficient duration
to see more significant correlations with
clinical parameters (33). Nonetheless, the
novel measurement of adherence that we
have described demonstrated significant
associations with several measures of
asthma over the timeframe, demonstrating
Table 6. Receiver operator curve analysis demonstrating the sensitivity and specificity
of each adherence measure in correlation to improvements in PEF and AQLQ
Adherence
Measure
PEF AQLQ
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
Actual adherence fðACÞ 59.8 46.9 66.7 44.6
Average adherence
from dose counter
19.5 71.9 19.2 73.7
Mean daily dose 27.1 69.7 25.0 73.3
Attempted adherence fðATÞ 32.5 63.6 37.5 66.0
Definition of abbreviations: AQLQ = Asthma Quality of Life Questionnaire; PEF = peak expiratory flow.
slope=–0.1
A
0
Av
er
ag
e 
Ad
he
re
nc
e 
(%
)
5 10 15 20 25
AM PM Variability
0
20
40
60
80
100
slope=–0.3
B
0
20
M
ea
n 
D
ai
ly 
Do
se
 (%
)
40
60
80
100
AM PM Variability
0 5 10 15 20 25
slope=–0.5
C
At
te
m
pt
ed
 A
dh
er
en
ce
 (%
)
AM PM Variability
0
0
20
40
60
80
100
5 10 15 20 25
slope=–0.8
D
Ac
tu
al
 A
dh
er
en
ce
 (%
)
AM PM Variability
0
0
20
40
60
80
100
5 10 15 20 25
Figure 5. Twice-daily peak expiratory flow (PEF) was divided into morning (A.M.) and evening (P.M.) readings. The mean variability between the A.M.
and the P.M. readings was calculated for each month for each patient. (A–D) Change in A.M.-P.M. PEF variability for the four measures of adherence,
(A) average adherence calculated from the dose counter, (B) the mean daily dose, (C ) attempted adherence [fðATÞ] and (D) actual adherence [fðACÞ].
actual adherence [fðACÞ] showed the most negative relationship with A.M.-P.M. PEF variability (slope, 20.8). There was a significant difference between
average adherence with both fðACÞ and fðATÞ (P = 0.01 and P = 0.03, respectively).
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its appropriateness. Future experimental
tests of the approach described here will
involve testing in larger populations and for
longer periods of time.
We have previously described the close
relationship of acoustically assessed PIF
with objectively measured PIF (14, 16, 17).
We have also described the significant effect
of both low PIF and that of exhalation into
the inhaler on drug delivery (14, 16, 17, 34).
For the purpose of calculating the impact of
inhaler technique errors on adherence, we
used a binary response (present/not
present), but different degrees of user errors
will have different impacts on drug delivery,
and this will need to be further evaluated
and incorporated into this method of
calculating adherence (14–17). Adherence
and nonadherence to an intervention has
serious and obvious implications for a
clinical trial. Variations in adherence
influence the statistical power of a study
and the effect size of different therapies and
have serious implications for estimates of
the incidence of adverse events. In addition,
knowing the adherence of a therapy in a
clinical trial can provide insight into patient
acceptability of a new treatment or new
inhaler device. The results of this study
highlight the limited sensitivity of the
currently used method of describing
adherence as a mean value.
The approach for calculation of actual
adherence [f ðACÞ] described here would be
useful for clinical trials involving a diverse
range of respiratory conditions, including
those requiring inhaled antibiotics or other
agents, where errors in timing or user
technique may directly affect drug
accumulation. This may also be important
in phase 2 studies in which adjustment for
patients achieving per protocol adherence
may help avoid type 2 errors in data
analysis.
Conclusions
We have developed a method of calculating
inhaler adherence modeled on the concepts
of drug pharmacokinetics that incorporates
both the time of use of an inhaler and the
technique used. This method not only
identifies which component of adherence is
deficient but is also more reflective of the
clinical changes expected from a medication
than are the current methods used to assess
adherence. n
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